EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Comparative cost per responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide-refractory multiple myeloma

Doris K Hansen iD, Xiaoxiao Lu, Omar Castaneda Puglianini iD, Eileen Zhang, Saad Z Usmani iD, Rameet Sachdev, Matthew Perciavalle, Denise De Wiest, Stephen Huo, Seina Lee, Zaina P Qureshi, Sundar Jagannath iD

Expert Review of Pharmacoeconomics & Outcomes Research · 16.03.2026 · 26 (3) · 369-378

DOI: 10.1080/14737167.2026.2634771 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 03.03.2026. Verfasst von Doris K Hansen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Johnson & Johnson, Legend Biotech USA Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaImmunotherapy, AdoptiveReceptors, Chimeric AntigenHumansLenalidomideStandard of CareProgression-Free SurvivalCost-Benefit AnalysisModels, EconomicDrug Resistance, NeoplasmAntineoplastic AgentsBiological Products

Stichwörter der Autor:innen

CAR T-cell therapycost-per-respondereconomicsimmunotherapy, adoptivemultiple myeloma

Substanzen

Lenalidomideaxicabtagene ciloleucelReceptors, Chimeric AntigenAntineoplastic AgentsBiological Products

Autor:innen und Institutionen

  • Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Global Real World Evidence, Janssen Scientific Affairs, LLC, Horsham, PA, USA.
  • PPD Evidera Health Economics & Market Access, Thermo Fisher Scientific, Waltham, MA, USA.
  • Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • U.S Medical Affair, Legend Biotech USA Inc, USA.
  • U.S Medical Affair, Janssen Scientific Affairs, LLC, Horsham, PA, USA.

ORCID-Profile: Doris K Hansen, Omar Castaneda Puglianini, Saad Z Usmani, Sundar Jagannath

Förderung

  • Johnson & Johnson
  • Legend Biotech USA Inc

Zitieren

APA

Hansen, D. K., Lu, X., Castaneda Puglianini, O., Zhang, E., Usmani, S. Z., Sachdev, R., Perciavalle, M., De Wiest, D., Huo, S., Lee, S., Qureshi, Z. P., & Jagannath, S. (2026). Comparative cost per responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide-refractory multiple myeloma. Expert Review of Pharmacoeconomics & Outcomes Research, 26(3), 369-378. https://doi.org/10.1080/14737167.2026.2634771

Vancouver

Hansen DK, Lu X, Castaneda Puglianini O, Zhang E, Usmani SZ, Sachdev R, et al. Comparative cost per responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide-refractory multiple myeloma. Expert Review of Pharmacoeconomics & Outcomes Research. 2026;26(3):369-378. doi:10.1080/14737167.2026.2634771

BibTeX
@article{Hansen2026,
  author = {Hansen, Doris K and Lu, Xiaoxiao and Castaneda Puglianini, Omar and Zhang, Eileen and Usmani, Saad Z and Sachdev, Rameet and Perciavalle, Matthew and De Wiest, Denise and Huo, Stephen and Lee, Seina and Qureshi, Zaina P and Jagannath, Sundar},
  title = {Comparative cost per responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide-refractory multiple myeloma},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2026},
  volume = {26},
  number = {3},
  pages = {369--378},
  doi = {10.1080/14737167.2026.2634771}
}
Kostenlos starten →